Carbapenem-resistant Klebsiella pneumoniae urinary tract infection following solid organ transplantation

Antimicrobial Agents and Chemotherapy

Volumn 59, Issue 1, 2015, Pages 553-557

  Brizendine, Kyle D ^a   Richter, Sandra S ^a   Cober, Eric D ^a   Van Duin, David ^b  

^a LERNER RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE; CARBAPENEM; COLISTIN; FOSFOMYCIN; TIGECYCLINE; ANTIINFECTIVE AGENT; BETA LACTAMASE; CARBAPENEM DERIVATIVE;

ADULT; ANTIBIOTIC THERAPY; ARTICLE; CARBAPENEM RESISTANT KLEBSIELLA PNEUMONIAE; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; EXTENDED SPECTRUM BETA LACTAMASE PRODUCING KLEBSIELLA PNEUMONIAE; EXTENDED SPECTRUM BETA LACTAMASE SUSCEPTIBLE KLEBSIELLA PNEUMONIAE; FEMALE; HEART TRANSPLANTATION; HOSPITAL PATIENT; HUMAN; INTENSIVE CARE UNIT; KIDNEY TRANSPLANTATION; KLEBSIELLA PNEUMONIAE; LENGTH OF STAY; LIVER TRANSPLANTATION; LUNG TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; ORGAN TRANSPLANTATION; RETROSPECTIVE STUDY; RISK FACTOR; URINARY CATHETER; URINARY TRACT INFECTION; ADVERSE EFFECTS; ANTIBIOTIC RESISTANCE; DRUG EFFECTS; KLEBSIELLA INFECTIONS; METABOLISM; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MIDDLE AGED; OHIO; PATHOGENICITY; STATISTICAL MODEL; TREATMENT OUTCOME; URINARY TRACT INFECTIONS;

ANTI-BACTERIAL AGENTS; BETA-LACTAMASES; CARBAPENEMS; COHORT STUDIES; DRUG RESISTANCE, BACTERIAL; FEMALE; HUMANS; INTENSIVE CARE UNITS; KLEBSIELLA INFECTIONS; KLEBSIELLA PNEUMONIAE; LENGTH OF STAY; LOGISTIC MODELS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; OHIO; ORGAN TRANSPLANTATION; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; URINARY TRACT INFECTIONS;

EID: 84920116106     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.04284-14     Document Type: Article

References (19)

1. Sievert DM, Ricks P, Edwards JR, Schneider A, Patel J, Srinivasan A, Kallen A, Limbago B, Fridkin S. 2013. Antimicrobial-resistant pathogens associated with healthcare-associated infections: summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2009-2010. Infect Control Hosp Epidemiol 34:1-14. http://dx.doi.org/10.1086/668770.
2. Centers for Disease Control and Prevention. 2014. CDC/NHSN surveillance definitions for specific types of infections. Centers for Disease Control and Prevention, Atlanta, GA. http://www.cdc.gov/nhsn/PDFs/pscManual/17pscNosInfDef-current.pdf.
3. Lautenbach E, Patel JB, Bilker WB, Edelstein PH, Fishman NO. 2001. Extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for infection and impact of resistance on outcomes. Clin Infect Dis 32:1162-1171. http://dx.doi.org/10.1086/319757.
4. Lee K, Chong Y, Shin HB, Kim YA, Yong D, Yum JH. 2001. Modified Hodge and EDTA-disk synergy tests to screen metallo-β-lactamaseproducing strains of Pseudomonas and Acinetobacter species. Clin Microbiol Infect 7:88-91. http://dx.doi.org/10.1046/j.1469-0691.2001.00204.x.
5. Alangaden GJ, Thyagarajan R, Gruber SA, Morawski K, Garnick J, El-Amm JM, West MS, Sillix DH, Chandrasekar PH, Haririan A. 2006. Infectious complications after kidney transplantation: current epidemiology and associated risk factors. Clin Transplant 20:401-409. http://dx.doi.org/10.1111/j.1399-0012.2006.00519.x.
6. Simkins J, Muggia V, Cohen HW, Minamoto GY. 2014. Carbapenemresistant Klebsiella pneumoniae infections in kidney transplant recipients: a case-control study. Transpl Infect Dis 16:775-782. http://dx.doi.org/10.1111/tid.12276.
7. Patel G, Huprikar S, Factor SH, Jenkins SG, Calfee DP. 2008. Outcomes of carbapenem-resistant Klebsiella pneumoniae infection and the impact of antimicrobial and adjunctive therapies. Infect Control Hosp Epidemiol 29:1099-1106. http://dx.doi.org/10.1086/592412.
8. Kalpoe JS, Sonnenberg E, Factor SH, del Rio Martin J, Schiano T, Patel G, Huprikar S. 2012. Mortality associated with carbapenem-resistant Klebsiella pneumoniae infections in liver transplant recipients. Liver Transpl 18:468-474. http://dx.doi.org/10.1002/lt.23374.
9. Clancy CJ, Chen L, Shields RK, Zhao Y, Cheng S, Chavda KD, Hao B, Hong JH, Doi Y, Kwak EJ, Silveira FP, Abdel-Massih R, Bogdanovich T, Humar A, Perlin DS, Kreiswirth BN, Hong Nguyen M. 2013. Epidemiology and molecular characterization of bacteremia due to carbapenemresistant Klebsiella pneumoniae in transplant recipients. Am J Transplant 13:2619-2633. http://dx.doi.org/10.1111/ajt.12424.
10. Lübbert C, Becker-Rux D, Rodloff AC, Laudi S, Busch T, Bartels M, Kaisers UX. 2014. Colonization of liver transplant recipients with KPCproducing Klebsiella pneumoniae is associated with high infection rates and excess mortality: a case-control analysis. Infection 42:309-316. http: //dx.doi.org/10.1007/s15010-013-0547-3.
11. Neuner EA, Sekeres J, Hall GS, van Duin D. 2012. Experience with fosfomycin for treatment of urinary tract infections due to multidrugresistant organisms. Antimicrob Agents Chemother 56:5744-5748. http://dx.doi.org/10.1128/AAC.00402-12.
12. Nguyen M, Eschenauer GA, Bryan M, O'Neil K, Furuya EY, Della-Latta P, Kubin CJ. 2010. Carbapenem-resistant Klebsiella pneumoniae bacteremia: factors correlated with clinical and microbiologic outcomes. Diagn Microbiol Infect Dis 67:180-184. http://dx.doi.org/10.1016/j.diagmicrobio.2010.02.001.
13. Neuner EA, Yeh JY, Hall GS, Sekeres J, Endimiani A, Bonomo RA, Shrestha NK, Fraser TG, van Duin D. 2011. Treatment and outcomes in carbapenem-resistant Klebsiella pneumoniae bloodstream infections. Diagn Microbiol Infect Dis 69:357-362. http://dx.doi.org/10.1016/j.diagmicrobio.2010.10.013.
14. Qureshi ZA, Syed A, Clarke LG, Doi Y, Shields RK. 2014. Epidemiology and clinical outcomes of patients with carbapenem-resistant Klebsiella pneumoniae bacteriuria. Antimicrob Agents Chemother 58:3100-3104. http://dx.doi.org/10.1128/AAC.02445-13.
15. Alexander BT, Marschall J, Tibbetts RJ, Neuner EA, Dunne WM, Jr, Ritchie DJ. 2012. Treatment and clinical outcomes of urinary tract infections caused by KPC-producing Enterobacteriaceae in a retrospective cohort. Clin Ther 34:1314-1323. http://dx.doi.org/10.1016/j.clinthera.2012.05.002.
16. Satlin MJ, Kubin CJ, Blumenthal JS, Cohen AB, Furuya EY, Wilson SJ, Jenkins SG, Calfee DP. 2011. Comparative effectiveness of aminoglycosides, polymyxin B, and tigecycline for clearance of carbapenem-resistant Klebsiella pneumoniae from urine. Antimicrob Agents Chemother 55: 5893-5899. http://dx.doi.org/10.1128/AAC.00387-11.
17. Bergamasco MD, Barroso Barbosa M, de Oliveira Garcia D, Cipullo R, Moreira JC, Baia C, Barbosa V, Abboud CS. 2012. Infection with Klebsiella pneumoniae carbapenemase (KPC)-producing K. pneumoniae in solid organ transplantation. Transpl Infect Dis 14:198-205. http://dx.doi.org/10.1111/j.1399-3062.2011.00688.x.
18. Cicora F, Mos F, Paz M, Allende NG, Roberti J. 2013. Infections with blaKPC-2-producing Klebsiella pneumoniae in renal transplant patients: a retrospective study. Transplant Proc 45:3389-3393. http://dx.doi.org/10.1016/j.transproceed.2013.07.064.
19. Raviv Y, Shitrit D, Amital A, Fox B, Bakal I, Tauber R, Bishara J, Kramer MR. 2012. Multidrug-resistant Klebsiella pneumoniae acquisition in lung transplant recipients. Clin Transplant 26:E388-E394. http://dx .doi.org/10.1111/j.1399-0012.2012.01671.x.